Semaglutide in Connecticut: Prices & Providers (2026)

318 of the 391 semaglutide sellers that publish a state list include Connecticut, the 30th-most of the 50 states and DC. 207 of them ship to all 50 states. Across the 237 with a regular monthly price, the middle figure is $179/mo.

Connecticut Medicaid does not pay for GLP-1 drugs prescribed only for weight loss. GLP-1s prescribed for type 2 diabetes are covered, with prior authorization.

The drug itself, including its dosing, side effects and cost, is covered on the semaglutide drug page, and how the state program handles it is in the Connecticut Medicaid GLP-1 coverage guide.

Who Ships Semaglutide to Connecticut

1. WellMedRx $49/mo
2. Collective $59/mo
3. RxPepsDirect $64/mo

Lowest regular semaglutide prices for Connecticut: WellMedRx at $49/mo, Collective at $59/mo and RxPepsDirect at $64/mo. Brand-name Wegovy lists at $1,349/mo without insurance, $1,300 more than the lowest; it is $349 a month direct from Novo Nordisk.

6 sellers that list 30 or more states leave Connecticut off, among them OurView Health, Trellis Vitality, Brello Health, Welm Health and Nimbus Healthcare.

Seller counts next door: Massachusetts 310, New York 335 and Rhode Island 300.

For tirzepatide, 308 sellers list Connecticut, starting at $69/mo with Collective.

What Semaglutide Costs in Connecticut

Brand-name Wegovy lists at $1,349/mo without insurance. It is $349 a month direct from Novo Nordisk.

Connecticut Medicaid and Wegovy

Connecticut Medicaid does not pay for GLP-1 drugs prescribed only for weight loss. GLP-1s prescribed for type 2 diabetes are covered, with prior authorization.

• Wegovy to cut heart attack and stroke risk: covered with prior authorization (age of at least 18; no type 1 or type 2 diabetes and no NYHA class IV heart failure; A1c under 6.5%; BMI of at least 27; prior heart attack, prior ischemic or hemorrhagic stroke, or symptomatic peripheral artery disease; lifestyle program; renewal: at least 5% weight loss from baseline).
• Wegovy for the liver disease MASH: covered with prior authorization (fibrosis stage F2-F3).

In 2025, Connecticut Medicaid paid for at least 107,061 semaglutide prescriptions, including at least 2,125 for Wegovy, at least 101,853 for Ozempic and at least 3,083 for Rybelsus, about $122.0 million before manufacturer rebates.

Medicaid rules checked November 2026. Prescription counts: CMS State Drug Utilization Data. Check your eligibility

Largest Cities in Connecticut

Frequently Asked Questions

Keep Reading

• Clinical-trial results and how we rank semaglutide providers